We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
CorMedix Banks on DefenCath Sales in Q4 as Melinta Adds Upside
Read MoreHide Full Article
Key Takeaways
CorMedix's Q4 revenues likely to be driven by strong DefenCath sales uptake in outpatient dialysis settings.
CRMD's Melinta acquisition expanded its portfolio, recording incremental sales from seven approved products.
Preliminary Q4 net revenues near $127M, supported by higher-than-expected DefenCath utilization.
The majority of CorMedix’s (CRMD - Free Report) revenues come from its lead product, DefenCath, which is approved as the first and only antimicrobial catheter lock solution in the United States. The product is indicated to reduce the incidence of catheter-related bloodstream infections (CRBSIs) in adult patients with kidney failure who receive chronic hemodialysis through a central venous catheter. CRBSIs can delay treatment, increase hospital stays, raise healthcare costs and increase the risk of death. Through DefenCath, CorMedix is addressing an important unmet medical need.
In the first nine months of 2025, DefenCath recorded $167.6 million in net sales, reflecting strong uptake trends. Like the previous three quarters of 2025, DefenCath is expected to remain a key top-line driver in the fourth quarter as well. The higher-than-expected utilization of DefenCath by outpatient dialysis customers is likely to have driven sales in the fourth quarter.
CorMedix recently reported preliminary fourth-quarter and full-year 2025 results, with net revenues of approximately $127 million and $310 million, respectively.
Management also introduced full-year 2026 revenue guidance of $300-$320 million, including $150-$170 million from DefenCath. Importantly, DefenCath’s 2026 revenue guidance is weighted toward the first half of the year.
Meanwhile, CorMedix took a major step in diversifying its business and reducing its high dependence on DefenCath with the acquisition of Melinta Therapeutics in August 2025. The acquisition added seven approved therapies to CRMD’s commercial portfolio, strengthening its presence in hospital acute care and infectious disease markets. These acquired products from Melinta generated $12.8 million in revenues for CorMedix in the third quarter of 2025, reflecting a partial quarter of sales.
CorMedix’s preliminary net revenues for the fourth quarter and full-year 2025 reflect the growing momentum with DefenCath and early Melinta portfolio contributions.
As CorMedix is gearing up to report fourth-quarter results, DefenCath is expected to have sustained strong sales growth and adoption, while the Melinta portfolio is likely to have provided incremental growth, supporting overall top-line momentum.
CRMD’s Competition in the Target Market
While CorMedix is currently benefiting from DefenCath’s success, it faces strong competition from larger, established players in the heparin market.
DefenCath is a fixed-dose combination of taurolidine, an antimicrobial agent, and heparin, designed for a specific group of kidney failure patients. While CorMedix currently enjoys a first-mover advantage in the United States, competition remains a key risk. Large companies such as Pfizer (PFE - Free Report) , Amphastar Pharmaceuticals (AMPH - Free Report) , B. Braun, Baxter and Fresenius Kabi USA already sell heparin for various uses.
Pfizer, which markets Heparin Sodium Injection for dialysis, surgery and thrombosis, could use its global scale to enter the CRBSI prevention space. Amphastar Pharmaceuticals, with end-to-end control over enoxaparin production, also has the efficiency and technical capabilities to pursue similar opportunities. If either Pfizer or Amphastar Pharmaceuticals expands into catheter-related infection prevention, CorMedix could face significant competitive pressure.
With broader pipelines, larger manufacturing capacity and stronger financial resources, these companies could quickly emerge as major competitors if they target catheter-related bloodstream infections, potentially weakening CorMedix’s market position and long-term growth prospects.
CRMD’s Stock Price, Valuation and Estimates
Shares of CorMedix have plunged 33.1% in the past six months against the industry’s growth of 23.9%. The stock has also underperformed the sector and the S&P 500 index during the same time frame, as seen in the chart below.
Image Source: Zacks Investment Research
From a valuation standpoint, CorMedix is trading at a discount to the industry. Going by the price/book ratio, the company’s shares currently trade at 1.62, lower than 3.73 for the industry. The stock is also trading below its five-year mean of 3.32.
Image Source: Zacks Investment Research
Estimates for CorMedix’s 2025 earnings have decreased from $2.85 to $2.78 per share in the past 30 days, while estimates for 2026 earnings have declined from $2.37 to $1.30 during the same timeframe.
Image Source: Zacks Investment Research
CRMD’s Zacks Rank
CorMedix currently carries a Zacks Rank #5 (Strong Sell).
View the Zacks #1 Rank List
Image: Bigstock
CorMedix Banks on DefenCath Sales in Q4 as Melinta Adds Upside
Key Takeaways
The majority of CorMedix’s (CRMD - Free Report) revenues come from its lead product, DefenCath, which is approved as the first and only antimicrobial catheter lock solution in the United States. The product is indicated to reduce the incidence of catheter-related bloodstream infections (CRBSIs) in adult patients with kidney failure who receive chronic hemodialysis through a central venous catheter. CRBSIs can delay treatment, increase hospital stays, raise healthcare costs and increase the risk of death. Through DefenCath, CorMedix is addressing an important unmet medical need.
In the first nine months of 2025, DefenCath recorded $167.6 million in net sales, reflecting strong uptake trends. Like the previous three quarters of 2025, DefenCath is expected to remain a key top-line driver in the fourth quarter as well. The higher-than-expected utilization of DefenCath by outpatient dialysis customers is likely to have driven sales in the fourth quarter.
CorMedix recently reported preliminary fourth-quarter and full-year 2025 results, with net revenues of approximately $127 million and $310 million, respectively.
Management also introduced full-year 2026 revenue guidance of $300-$320 million, including $150-$170 million from DefenCath. Importantly, DefenCath’s 2026 revenue guidance is weighted toward the first half of the year.
Meanwhile, CorMedix took a major step in diversifying its business and reducing its high dependence on DefenCath with the acquisition of Melinta Therapeutics in August 2025. The acquisition added seven approved therapies to CRMD’s commercial portfolio, strengthening its presence in hospital acute care and infectious disease markets. These acquired products from Melinta generated $12.8 million in revenues for CorMedix in the third quarter of 2025, reflecting a partial quarter of sales.
CorMedix’s preliminary net revenues for the fourth quarter and full-year 2025 reflect the growing momentum with DefenCath and early Melinta portfolio contributions.
As CorMedix is gearing up to report fourth-quarter results, DefenCath is expected to have sustained strong sales growth and adoption, while the Melinta portfolio is likely to have provided incremental growth, supporting overall top-line momentum.
CRMD’s Competition in the Target Market
While CorMedix is currently benefiting from DefenCath’s success, it faces strong competition from larger, established players in the heparin market.
DefenCath is a fixed-dose combination of taurolidine, an antimicrobial agent, and heparin, designed for a specific group of kidney failure patients. While CorMedix currently enjoys a first-mover advantage in the United States, competition remains a key risk. Large companies such as Pfizer (PFE - Free Report) , Amphastar Pharmaceuticals (AMPH - Free Report) , B. Braun, Baxter and Fresenius Kabi USA already sell heparin for various uses.
Pfizer, which markets Heparin Sodium Injection for dialysis, surgery and thrombosis, could use its global scale to enter the CRBSI prevention space. Amphastar Pharmaceuticals, with end-to-end control over enoxaparin production, also has the efficiency and technical capabilities to pursue similar opportunities. If either Pfizer or Amphastar Pharmaceuticals expands into catheter-related infection prevention, CorMedix could face significant competitive pressure.
With broader pipelines, larger manufacturing capacity and stronger financial resources, these companies could quickly emerge as major competitors if they target catheter-related bloodstream infections, potentially weakening CorMedix’s market position and long-term growth prospects.
CRMD’s Stock Price, Valuation and Estimates
Shares of CorMedix have plunged 33.1% in the past six months against the industry’s growth of 23.9%. The stock has also underperformed the sector and the S&P 500 index during the same time frame, as seen in the chart below.
Image Source: Zacks Investment Research
From a valuation standpoint, CorMedix is trading at a discount to the industry. Going by the price/book ratio, the company’s shares currently trade at 1.62, lower than 3.73 for the industry. The stock is also trading below its five-year mean of 3.32.
Image Source: Zacks Investment Research
Estimates for CorMedix’s 2025 earnings have decreased from $2.85 to $2.78 per share in the past 30 days, while estimates for 2026 earnings have declined from $2.37 to $1.30 during the same timeframe.
Image Source: Zacks Investment Research
CRMD’s Zacks Rank
CorMedix currently carries a Zacks Rank #5 (Strong Sell).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.